TMS Company
A Tokyo-based clinical-stage biotech company. Lead program TMS-007 (acute ischemic stroke) is partnered with Biogen.
Technology:
Cancer
Industry:
PharmTech
Headquarters:
Fuchu, Tokyo, Japan
Founded Date:
2005
Employees Number:
11-50
Estimated Revenue:
$1M to $10M
Register and Claim Ownership